semaglutide and cardiac risk Cardiovascular Outcomes in Obesity without Diabetes Semaglutide Cuts Heart Risk 29%

Gastrointestinal (digestive tract) side effects are the most common side effects reported with these medications

Our recent work demonstrated that oxidized low-density lipoprotein (LDL) upregulates DPP-4 expression on macrophages via activation of Toll-like receptor 4 (TLR4)/TIR-domain-containing adapter-inducing interferon- (TRIF) and CD36 pathways [36]

Recent labs are required prior to taking most weight loss medications as part of our weight loss program in California

Meta-analyses pooling trial data indicated statistically significant differences favoring tirzepatide for percent weight loss, but semaglutide remained highly effective and better tolerated by some participants, notably in community practice